drugset / Trial / NCT00940628

A Study of Xenical (Orlistat) in Overweight and Obese Adolescents

NCT00940628

Phase 3 Completed 60 enrolled Hoffmann-La Roche
Non-randomizedOpen-labelTreatment

Summary

This 2 arm study will assess the effect of Xenical on body mass index (BMI)in obese or overweight adolescents. Patients will be randomised into one of 2 groups; both groups will undergo a regimen of mildly hypocaloric diet and physical exercise, but one group will also receive Xenical 120mg po tid. The anticipated time on study treatment is 1 year, and the target sample size is \<100 individuals.

Timeline

Start
2008-04
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Orlistat Small molecule 120 mg Oral

Indications